[ad_1]
Ghana today received 98,400 doses of the Covid-19 AstraZeneca vaccine which were donated by Norway through the COVAX facility.
COVAX is a global initiative co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi (The Vaccines Alliance) and the World Health Organization, which works with governments and manufacturers to accelerate development, production and equitable access to Covid-19. vaccines around the world.
Country President for Africa AstraZeneca Barbara Nel said: “I was delighted to see 98,400 doses of the COVID-19 AstraZeneca vaccine arrive today at Kotoka International Airport.
“This donation from Norway will strengthen Ghana’s immunization program and is great news for the people of Ghana.
“Today’s arrival demonstrates the value of governments, industry and others working together to meet our continent’s urgent vaccine access needs.
“We will continue to advocate for equitable vaccine distribution and for more vaccines to arrive in Africa this year and in 2022. In this regard, AstraZeneca’s commitment to Africa remains steadfast,” she said. .
AstraZeneca was the first global pharmaceutical company to join COVAX in June 2020, and more than 113 million doses of the company’s vaccine have been delivered via COVAX to date.
AstraZeneca is committed to providing the vaccine widely and equitably around the world, without profit during the pandemic period.
To date, more than one billion doses of the Covid-19 AstraZeneca vaccine have been distributed in more than 170 countries around the world, and about two-thirds have gone to low- and lower-middle-income countries.
AstraZeneca is the third largest supplier of Covid-19 vaccine doses in the world. Since its first international launch in early 2021, the vaccine has prevented hundreds of thousands of hospitalizations and saved tens of thousands of lives.
AstraZeneca Covid-19 vaccine
The Covid-19 AstraZeneca vaccine (ChAdOx1-S [Recombinant]), formerly AZD1222, was co-invented by the University of Oxford and its spin-off company, Vaccitech.
It uses a replication-deficient chimpanzee viral vector based on a weakened version of a cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material for the SARS-CoV-2 virus spike protein.
After vaccination, the spike surface protein is produced, prompting the immune system to attack the SARS-CoV-2 virus if it later infects the body.
Source link
